Dr. Markos Leggas
Dr. Markos Leggas

Associate Professor

Dr. Leggas joined the University of Kentucky College of Pharmacy in 2004 and his research efforts have focused on translational projects in the area of anticancer drug development. Currently, Dr. Leggas has NCI and industrial funding for the clinical development of a novel anticancer agent, DB-67, which is in Phase I clinical trials. Another major emphasis of the laboratory is placed in the pharmacokinetics and pharmacodynamics of nanoparticle and/or liposomal anticancer drug formulations. In addition Dr. Leggas is studying the role of transporter proteins on the disposition of physiological substrates and anticancer drugs as well as in the development of tumor drug resistance.

Recent Publications

  • Shaaban K A, Elshahawi S I, Wang X, Horn J, Kharel M K, Leggas Markos, Thorson Jon S. (2015). Cytotoxic indolocarbazoles from Actinomadura melliaura ATCC 39691. Journal of Natural Products, 78(7), 1723-9.
  • Wang Yi-Tin, Liu X, Pijut S S, Li J, Horn J, Bradford E M, Leggas Markos, Barrett Terrence Anthony, Graf Gregory A. (2015). The combination of ezetimibe and ursodiol promotes fecal sterol excretion and reveals a G5G8-independent pathway for cholesterol elimination. Journal of lipid research,
  • Bada-Ellzey Henrietta S, Sithisarn Thitinart, Gibson Jacqueline S, Garlitz K, Caldwell R, Capilouto Gilson J, Li Y, Leggas Markos, Breheny Patrick John. (2015). Morphine versus clonidine in neonatal abstinence syndrome: A randomized trial and pilot study. Pediatrics, 135(2), e383-e391.
  • Chen J M, Shepherd M D, Horn J, Leggas Markos, Rohr Jurgen. (2014). Enzymatic methylation and structure-activity-relationship studies on polycarcin v, a gilvocarcin-type antitumor agent. Chembiochem : a European journal of chemical biology, 15(18), 2729-35.
  • Ahmed T A, Hayslip John Watson, Leggas Markos. (2014). Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition. Leukemia research, 38(11), 1350-7.
  • Tsakalozou E, Adane E D, Liang Ying, Arnold Susanne Markesbery, Leggas Markos. (2014). Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans. Cancer chemotherapy and pharmacology, 74(1), 45-54.
  • Shu Y, Pi F, Sharma A, Rajabi M, Haque Farzin, Shu Dan, Leggas Markos, Evers B Mark, Guo Peixuan. (2014). Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Advanced drug delivery reviews, 66C, 74-89.
  • Ahmed T A, Hayslip John Watson, Leggas Markos. (2013). Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients. Cancer chemotherapy and pharmacology, 72(6), 1369-74.
  • Tsakalozou E, Adane E D, Kuo K L, Daily A, Moscow Jeffrey A, Leggas Markos. (2013). The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro. Drug metabolism and disposition: the biological fate of chemicals, 41(7), 1404-13.
  • Evers B Mark, Li Tonglei, Hollis C P, Weiss Heidi L, Leggas Markos, Gemeinhart R A. (2013). Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: Lessons Learned of the EPR effect and image-guided drug delivery. Journal of Controlled Release, 172, 12-21.